Digoxin levels should be kept to a minimum in men with heart failure

doi:10.1136/bmj.326.7387.468/e

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Scott Gottlieb

New York

The heart drug digoxin seems to increase survival in men with heart failure but only when the blood level of the drug is kept to a minimum. With higher levels, the drug provides no benefit and may even be harmful (JAMA 2003;289:871-8).

The new findings are based on a post hoc analysis of data from the Digitalis Investigation Group (DIG) trial, conducted from August 1991 to December 1995 and published in 1997. The DIG trial seemed to show that digoxin did not increase survival but did help to keep patients out of hospital …